ICAM1 and dry eye syndrome: Our group recently showed that the addition of a single ICAM-1 binding peptide (IBP) to a protein nanocarrier administered intravenously can transiently increase the accumulation of this nanocarrier in the LG in the NOD mouse model of autoimmune-mediated dry eye, relative to the untargeted nanocarrier [20].